Illumina Inc.
No price chart data available for 1D timeframe.
Rating
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
Illumina, Inc. specializes in delivering advanced genetic and genomic analysis tools, primarily through sequencing and array technologies. The company's offerings empower clients across various sector...
Latest News
5 hours ago · zacks.com
Why Illumina (ILMN) is a Top Growth Stock for the Long-TermThe Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
6 hours ago · zacks.com
Don't Overlook Illumina (ILMN) International Revenue Trends While Assessing the StockExplore Illumina's (ILMN) international revenue trends and how these numbers impact Wall Street's forecasts and what's ahead for the stock.
3 days ago · zacks.com
ILMN Q3 Earnings Call Highlights Higher Guidance and Clinical GrowthIllumina raises its 2026 guidance as strong clinical sequencing demand and NovaSeq X adoption fuel growth despite research weakness and pricing pressures.
3 days ago · zacks.com
Illumina (ILMN) Reports Q3 Earnings: What Key Metrics Have to SayAlthough the revenue and EPS for Illumina (ILMN) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
3 days ago · seekingalpha.com
Illumina, Inc. (ILMN) Q3 2026 Earnings Call TranscriptIllumina, Inc. (ILMN) Q3 2026 Earnings Call Transcript
3 days ago · zacks.com
Illumina (ILMN) Q3 Earnings Beat EstimatesIllumina (ILMN) came out with quarterly earnings of $1.44 per share, beating the Zacks Consensus Estimate of $1.36 per share. This compares to earnings of $1.34 per share a year ago.
3 days ago · marketbeat.com
Illumina Q3 Earnings Call HighlightsIllumina NASDAQ: ILMN reported third-quarter results above its prior guidance, citing strong clinical sequencing demand, elevated NovaSeq X instrument placements and disciplined spending. The company raised its full-year revenue, operating-margin and earnings outlook, while executives said they remain on track toward longer-term growth targets.
3 days ago · benzinga.com
Illumina Q3 2026 Earnings Call TranscriptIllumina (NASDAQ:ILMN) reported third-quarter financial results on Thursday. The transcript from the company's third-quarter earnings call has been provided below.
3 days ago · prnewswire.com
Illumina Reports Financial Results for Third Quarter of Fiscal Year 2026SAN DIEGO, Oct. 29, 2026 /PRNewswire/ -- Illumina, Inc. (Nasdaq: ILMN) ("Illumina" or the "company") today announced its financial results for the third quarter of fiscal year 2026. Third quarter 2026 results Reported revenue was $1.13 billion for Q3 2026, up 4.2% from Q3 2025.
5 days ago · zacks.com
Illumina (ILMN) Q3 Earnings on the Horizon: Analysts' Insights on Key Performance MeasuresEvaluate the expected performance of Illumina (ILMN) for the quarter ended September 2026, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Earnings
Analyst Summary
Add to Watchlist
Select watchlists to add or remove ILMN